一个基于人群的传染病死亡风险研究在患有血液恶性瘤的患者中2000-2020年
Wenshuai Zheng1, Shenyu Wang2, Bo Peng2
1Department of Hematology, Hainan Hospital of Chinese PLA General Hospital, Sanya, Hainan, China.
Cancer medicine
|April 1, 2025
概括
患有血液癌症的患者面临着因感染而死亡的高风险. 这项研究发现,与一般人群相比,这些患者的传染病死亡率明显高于一般人群,这突显了早期干预的必要性.
科学领域:
- 血液学 血液学 血液学
- 传染性疾病 传染性疾病
- 流行病学 流行病学
背景情况:
- 患有血液性恶性瘤的患者患有传染病死亡的风险很高.
- 这种人群中的传染病死亡率 (IDM) 得到了有限的研究关注.
- 了解IDM趋势和风险因素对于改善患者的治疗结果至关重要.
研究的目的:
- 确定血液恶性瘤患者中IDM的发生率和趋势.
- 在这个患者群体中确定与IDM相关的风险因素.
- 将血液恶性瘤患者的IDM风险与美国普通人口进行比较.
主要方法:
- 利用了来自监测,流行病学和最终结果 (SEER) 计划 (2000-2020) 的数据.
- 计算了标准化死亡率 (SMR) 和IDM率.
- 采用竞争风险模型来确定IDM的潜在风险因素.
主要成果:
- 在700678名患者中确定了15028例IDM病例,IDM率为每10万人/年401.31.
- 观察到的SMR为3.34,表明与一般人群相比,IDM的风险显著增加,在随访期间持续存在.
- 在所有血液癌症亚型中,IDM的发病率在诊断后的头两个月内达到顶峰,随后下降. 早期诊断期,年龄较大,男性性别,黑人种族,单身/离婚/寡妇身份以及缺乏化疗或放射治疗被确定为危险因素. 晚期是淋巴瘤亚型的危险因素.
结论:
- 传染病死亡率对患有血液性恶性瘤的患者构成重大威胁.
- 识别IDM高风险个体对于及时干预至关重要.
- 预防因感染导致的早期死亡可以改善这些患者的整体预后.
相关概念视频
Regulation of Hematopoietic Stem Cells
3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K
Hematopoiesis
4.9K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
4.9K
Bone Marrow Sampling and Transplants
266
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
266
Cancer Survival Analysis
311
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
311
Disorders of Leukocytes
772
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
772


